Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.

This study demonstrates that patients with benign prostatic hyperplasia have a higher severity and frequency of male pattern baldness compared to a control group.

This paper discusses the first reported case of post-finasteride syndrome in a long-term dermatotrichology setting, occurring in a 25-year-old male after dutasteride treatment, and highlights possible links to mental health disorders.

This meta-analysis found that male pattern baldness is associated with an increased risk of aggressive prostate cancer and benign prostatic hyperplasia.

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.

This study concluded that 16β-methyl-17α-benzoyloxypregnen-4-en-3,20-dione may be a promising treatment for androgen-dependent diseases and epilepsy due to its antioxidant effects and impact on GABAergic and serotonergic metabolism in rats.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

This study found that men with early-onset androgenetic alopecia had larger prostate volumes and lower urinary flow rates compared to those without the condition, suggesting a potential link between AGA and urinary symptoms.

This study found that early-onset androgenic alopecia is associated with a higher risk of developing prostate cancer, although it was not linked to earlier diagnosis or more aggressive tumors.

This article proposes that androgenic alopecia might be an evolutionary mechanism for reducing prostate cancer risk by enhancing UV absorption, rather than being a risk factor.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

This review discusses the expression of PSA in hormonally-regulated tissues and female malignancies, emphasizing its potential as a diagnostic biomarker and role in antidoping initiatives.

Finasteride treats hair loss but may affect prostate cancer detection.

This study reported that high cholesterol levels were linked to increased prostate cancer risk, while selenium supplementation affected gene expression, suggesting nutritional and clinical factors might influence prostate cancer risk and biology.

This study identifies mutations in the SRD5A3 gene as a cause of a new type of congenital disorder of glycosylation, impacting mental, ophthalmologic, and cerebellar functions.

This study reports that three synthesized PSMA-targeted radioimaging agents demonstrated high affinity and specific localization to prostate cancer tumors in a mouse model, highlighting their potential for cancer detection and monitoring.

This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.

This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.

This review discusses the hormonal influences on prostate carcinogenesis and notes ongoing trials investigating whether finasteride could reduce prostate cancer incidence by inhibiting dihydrotestosterone synthesis, but it reports no new results.

This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

In this study, corn silk extract treatment improved symptoms of testosterone-induced BPH by reducing specific mRNA expression and decreasing levels of 5α-R2, DHT, and PSA.

This review discusses the potential link between long-term transdermal exposure to sex hormones from antiperspirants and increased breast and prostate cancer rates, calling for further research to confirm this theory.

This review discusses the management of androgenic disorders in women, highlighting that treatment is generally more effective than recognized, though improvement may take weeks or months to appear.

In this study, serum PSA levels were higher in women with PCOS, suggesting it may serve as a marker for hyperandrogenism in this condition.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.